<DOC>
	<DOCNO>NCT02426723</DOCNO>
	<brief_summary>This Phase 1a/1b , multicenter , open-label , two-part study subject relapse refractory MM : - Phase 1a : single agent CWP232291 . Dose-finding follow cohort expansion maximum tolerate dose ( MTD ) optimal dose determine Safety Review Committee ( SRC ) . - Phase 1b : CWP232291 combination lenalidomide dexamethasone . Dose-finding follow cohort expansion combination therapy MTD optimal dose determine SRC .</brief_summary>
	<brief_title>Clinical Study CWP232291 Relapsed Refractory Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Able understand sign inform consent form ( ICF ) prior initiation studyspecific procedure treatment . 2 . ≥ 18 year age . 3 . Confirmed measurable MM base following : Serum M component ( ≥ 0.5 g/dL ) , Urine M protein ≥ 200 mg/24 hour ) , Serum immunoglobulin free light chain ≥ 10 mg/dL abnormal serum immunoglobulin kappa/lambda free light chain ratio ) , Nonsecretory disease measurable bone marrow biopsy radiography . 4 . Failed 2 prior standard MM therapy , &gt; 100 day post autologous bone marrow transplant prior first dose transplant subject . Prior lenalidomide permit . 5 . In absence rapidly progress disease , interval prior treatment time study drug administration ≥ 2 week cytotoxic agent least 5 halflives noncytotoxic agent . Persistent clinically significant toxicity prior chemotherapy radiotherapy must great Grade 1 . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 ( Appendix 3 ) . 7 . Adequate bone marrow function : Absolute neutrophil count ( ANC ) ≥ 1000/mm3 , independent growth factor support ; Platelet count ≥ 75,000/mm3 ; Hb ≥ 9 g/dL ( independent transfusion erythropoiesisstimulating agent [ ESA ] ) . 8 . Adequate renal function : Serum creatinine ≤ 2.5 mg/dL ; Creatinine clearance ( CrCl ) ≥ 60 mL/minute ( CockcroftGault ) . 9 . Adequate hepatic function : Total bilirubin &lt; 2.5 x upper limit normal ( ULN ) ; direct bilirubin &lt; 2 x ULN Gilbert 's syndrome ; Alkaline phosphatase ( AP ) ≤ 2.5 x ULN , unless consider due organ leukemic involvement ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN . 11 . Women childbearing potential ( ie , woman premenopausal surgically sterile ) : Two effective form contraception ( abstinence , intrauterine device , oral contraceptive , double barrier device ) time informed consent least 4 week discontinue study drug , Negative serum urine pregnancy test screen within 3 day prior Day 1 . 12 . Sexually active men effective contraceptive method subject partner time inform consent ≥ 4 week discontinue study drug . 13 . Able adhere study visit schedule protocol requirement . 1 . Chemotherapy immunotherapy &lt; 5 halflives prior screen . 2 . Not recover Grade 1 adverse effect prior myeloma therapy radiotherapy prior screen . 3 . Systemic corticosteroid &lt; 1 week prior Day 1 Phase 1a . Subjects may receive stable physiologic replacement dos glucocorticoid ( equivalent 10 mg daily prednisone ) maintenance therapy adrenal insufficiency . 4 . Uncontrolled intercurrent illness include infection psychiatric illness/social situation may limit compliance protocol requirement evaluation study drug . 5 . Active cardiovascular disease include myocardial infarction ( MI ) &lt; 6 month screen , symptomatic coronary artery disease ( CAD ) , arrhythmias , hypertension , heart failure control medication . 6 . History deep venous thrombosis pulmonary embolism ( Phase 1b ) . 7 . Anticoagulants &lt; 7 day prior Day 1 . Aspirin permit Phase 1b per standard care lenalidomidebased therapy . 8 . Active central nervous system ( CNS ) disease . 9 . Known positive status human immunodeficiency virus ( HIV ) and/or active hepatitis B C. 10 . Pregnant nursing woman . 11 . History hypersensitivity lenalidomide ( Part B ) 12 . History active malignancy &lt; 3 year prior screen except basal cell carcinoma , low grade Gleason score ≤ 6 prostate cancer remove undetectable prostatespecific antigen ( PSA ) , situ cervical carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>